Mianserin
| Mianserin | |
|---|---|
| Salts [] | |
|---|---|
| Mianserin hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 264.40 g/mol [1] |
| Solubility | 2.32e-01 g/L [1] |
| Predicted LogP | 3.4 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C18H20N2 |
| IUPAC name | 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene |
| SMILES | CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42 |
| InChI | InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3 |
| InChIKey | UEQUQVLFIPOEMF-UHFFFAOYSA-N |
| CAS number | 24219-97-4 |
| UNII | 250PJI13LM |
| PubChem CID | 4184 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 21–61 hours |
| Metabolism | Liver (CYP2D6; via aromatic hydroxylation, N-oxidation, N-demethylation) |
| Excretion | Urine: 4–7%, Feces: 14–28% |
| Routes of administration | By mouth |
Mianserin (also known as Mianserine, Mianserina, Mianserinum, Tolvon, 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine, J16.389i, Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, 1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine, Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- or 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine) is a substance of the phenethylamine class.
Chemistry
Salts []
Stereochemistry []
Mianserin is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Mianserin matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- other antidepressants (N06AX)
- (N06AX03)
- mianserin (N06AX03)
MeSH Classification
- adrenergic alpha-antagonists (M0000493)
- histamine h1 antagonists (M0010395)
- serotonin antagonists (M0019685)
- antidepressive agents, second-generation (M0028000)
Mechanism of action []
Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | induction / metabolism / inhibition | 74 (2 contraindicated) |
|---|---|---|
| CYP2D6 | inhibition / metabolism / induction | 16 (1 contraindicated) |
| CYP1A2 | metabolism / induction / inhibition | 12 (2 contraindicated) |
| ADRA2A | shared target | 3 (1 contraindicated) |
| ADRA2B | shared target | 3 (1 contraindicated) |
| ADRA2C | shared target | 3 (1 contraindicated) |
| HTR2A | shared target | 1 |
Medical side effects []
69 side effects listed on drug labels in SIDER 4.1 (mianserin).
- Headache
- Tremor
- Diplopia
- Nasal congestion
- Neuroleptic malignant syndrome
- Paraesthesia
- Restless legs syndrome
- Convulsion
- Agitation
- Hyperkinesia
- Bradycardia
- Agranulocytosis
- Anaemia
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Arthritis
- Asthenia
- Fatigue
- Mental disorder
- Breast disorder
- Confusional state
- Feeling abnormal
- Connective tissue disorder
- Constipation
- Dizziness
- Syncope
- Somnolence
- Oedema
- Dermatitis
- Rash
- Eye disorder
- Gastrointestinal disorder
- Gynaecomastia
- Cardiac arrest
- Cardiac disorder
- Cardiac failure
- Blood disorder
- Hepatitis
- Hypertension
- Hypotension
- Jaundice
- Lethargy
- Leukopenia
- Mediastinal disorder
- Nervous system disorder
- Neutropenia
- Pancytopenia
- Bone marrow depression
- Pruritus
- Shock
- Loss of consciousness
- Tachycardia
- Thrombocytopenia
- Tinnitus
- Torsade de pointes
- Angiopathy
- Vertigo
- Weight increased
- Dry mouth
- Depressive symptom
- Hepatic function abnormal
- Electrocardiogram QT prolonged
- Skin disorder
- Hepatic enzyme increased
- Hypomania
- Erectile dysfunction
- Hepatobiliary disease
- Suicidal ideation
Indications
- Major depression
Legal status []
- Australia: Mianserin is a Schedule 4.
- Brazil: Mianserin is a C1.[3]
- United Kingdom: Mianserin is Prescription only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4184, Mianserin. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4184
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Mianserin. UNII: 250PJI13LM. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/250PJI13LM
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 19:00:33 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 19:00:29 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 19:00:29 |
| gsrs | ok | 2026-11-20 19:00:30 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015620) | 2026-11-20 19:00:29 |
| kegg | ok | 2026-11-20 19:00:31 |
| pubchem | ok | 2026-11-20 19:00:27 |
| missing (no r/tripreports posts mention it) | 2026-11-20 19:00:29 | |
| sider | ok | 2026-11-20 19:00:29 |
| structure | ok | 2026-11-20 19:00:29 |
| wikipedia | ok | 2026-11-20 19:00:29 |